Breath volatile organic compounds as non-invasive biomarkers of detection and monitoring of inflammatory bowel disease

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200055543

Enrollment

Unknown

Registered

2022-01-11

Start date

2020-10-01

Completion date

Unknown

Last updated

2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

inflammatory bowel disease

Interventions

Gold Standard:Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing)

Index test:Chinese&#32

consensus&#32

on&#32

diagnosis&#32

and&#32

in&#32

(2018,&#32

Beijing)

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: IBD test group: 1. Aged 18 to 75 years, no gender restrictions; 2. Patients diagnosed with IBD by colonoscopy, histopathological examination and imaging examination. (1) Remission: CDAI 1; (2) Mild activity: CDAI 5-7; Ulcerative colitis with Mayo Risk score 3-5; (3) Moderate activity: CDAI 8-16; Ulcerative colitis has a Mayo risk score of 6-10; (4) Severe activity: CDAI >= 16. Ulcerative colitis Mayo Risk score 11-12. Control group: 1. Aged 18 to 75 years, no gender restrictions; 2. Healthy people with no significant lesions by colonoscopy and patients diagnosed with colonic polyps.

Exclusion criteria

Exclusion criteria: Subjects suffering from other digestive system diseases, respiratory system diseases, immune system diseases, blood system diseases, diabetes, kidney diseases and other metabolic diseases, and malignant tumors.

Design outcomes

Primary

Measure	Time frame
volatile organic compounds;sensitivity, specificity and accuracy;	—

Countries

China

Contacts

Public ContactWu Kaichun

Air Force Medical University

kaicwu@fmmu.edu.cn+86 13709218743

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026